Phuturdex › Drugs › Sabestomig
Drugs in development · updated 13 November 2026
Sabestomig: clinical trials and development status
Other names and codes: AZD7789
As of 13 November 2026 Sabestomig is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 7 diseases. The most advanced phase is I–II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
US-listed companies sponsoring active trials: AstraZeneca (NYSE: AZN, 2 trials). Data from official sources, not financial advice.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody AZD7789 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Non-small-cell lung carcinoma | I–II | 2 | NCT04931654 |
| Stomach neoplasm | I–II | 1 | NCT04931654 |
| Head and neck neoplasms | Early I | 1 | NCT04541108 |
| Head and neck squamous cell carcinoma | Early I | 1 | NCT04541108 |
| Lymphoma | Early I | 1 | NCT04541108 |
| Melanoma | Early I | 1 | NCT04541108 |
| Sarcoma | Early I | 1 | NCT04541108 |
Sites in Europe
19 sites of the active trials in 6 European countries, 0 recruiting.
- Spain5
- Italy4
- Poland4
- France3
- Belgium2
- Netherlands1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Sabestomig
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.